The main mechanism of action of Ezaphosphine is its interaction with the cell wall, which leads to an increase in the activity of phosphofructokinase, an increase in the intracellular supply of energy-rich phosphorus compounds and an influx of potassium ions into the cell.

Ezaphosphines in patients with acute myocardial infarction leads to improved hemodynamics, limitation of the size of the zone of myocardial necrosis, an increase in cardiac index and stroke volume, and an improvement in the ECG.

Phosphate is the main anion of intracellular fluids. It is present in blood plasma in both inorganic and organic forms and is a component of phospholipids, coenzymes and nucleic acids. Phosphates play an important role in various physiological processes, for example, they participate in the construction of high-energy bonds (ATP), transport of oxygen to tissues (2,3-diphosphoglycerate), regulation of glycolysis, maintaining the pH of blood plasma and urine.

In adults, phosphate levels normally range from 0.8 to 1.5 mmol/L.

Hypophosphatemia can often be observed in a wide range of clinical situations, both acute (blood transfusions, use of extracorporeal circulation) and chronic, such as alcoholism and hangover, long-term use of phosphate-binding antacids, severe and large burns, diabetic ketoacid. alkalosis, recovery period after surgery, hyperparathyroidism, vitamin D deficiency. It has been noted that taking phosphates improves the function of the respiratory muscles in patients with respiratory failure due to chronic obstructive pulmonary disease and malnutrition, accompanied by hypophosphate. Severe hypophosphatemia can often occur in patients receiving parenteral nutrition when they receive insufficient phosphate.

Clinical signs of hypophosphatemia, such as paresthesia, muscle hypotonia, and hyperventilation, most often occur with severe phosphate deficiency. In the absence of pronounced clinical manifestations, phosphate deficiency may indicate a violation of certain metabolic functions. It has also been found that obtaining sufficient phosphorus is important for the normal absorption of amino acids and carbohydrates during parenteral nutrition. Administration of actively metabolized organic phosphates, such as fructose-1,6-bisphosphate, can quickly restore physiological phosphate levels in the blood plasma. The results of biochemical studies in vitro and in vivo also indicate that FDF in pharmacological doses interacts with cell membranes, accelerates the absorption of potassium from the circulating blood by cells and stimulates an increase in the intracellular supply of high-energy phosphates and the accumulation of 2,3-diphosphoglycerate.

In total parenteral nutrition formulas, the compatibility of fructose-1,6-bisphosphate with cations, in particular calcium ion, is much higher than that of inorganic phosphates.

5 minutes after the end of administration at a dose of 250 mg/kg, the concentration in the blood plasma is 770 ml/l. 80 minutes after administration, no significant concentration of the drug was recorded in the blood plasma. The half-life from plasma is 10 to 15 minutes. FDF disappears from the blood plasma due to its distribution in the extravascular space and rapid conversion into monophosphate, triose phosphates and inorganic phosphates under the action of phosphatase and other enzymes present in the erythrocyte membrane and blood plasma.

Contraindications

Hereditary fructose intolerance, hyperphosphatemia, renal failure, hypersensitivity to the active or excipient of the drug.

Compound

1 bottle of lyophilized powder contains the active ingredient: D-fructose-1,6-diphosphate sodium salt hydrate 5 g, equivalent to 3.75 g of D-fructose-1,6-diphosphoric acid.

1 bottle of diluent contains excipients: water for injection.

The reconstituted solution contains 100 mg/ml D-fructose-1,6-diphosphate sodium salt hydrate equivalent to 75 mg/ml D-fructose-1,6-diphosphoric acid. This solution contains about 0.47 mEq/ml phosphorus.

Release form

Lyophilized powder for the preparation of solution for infusion (1 bottle of 5 g complete with 1 bottle of 50 ml of solvent and an infusion system in a cardboard box).

Basic physical and chemical properties

Hygroscopic crystalline powder, white or yellow. The reconstituted (prepared) solution is a clear, colorless or light yellow liquid.